Alpha 2.0
Login Register
» Authors » Olga Anagnostou

Olga Anagnostou

Explore the profile of Olga Anagnostou including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 66
Followers 0
Related Specialties
Gastroenterology
General Medicine
Psychiatry
Top 10 Co-Authors
Spilios Manolakopoulos
Angelos Hatzakis
Vana Sypsa
George Papatheodoridis
Apostolos Vantarakis
Melanie Deutsch
John Goulis
Ioannis Elefsiniotis
Agis Terzidis
George V Papatheodoridis
Published In
Ann Gastroenterol
Eur J Gastroenterol Hepatol
J Infect Dis
JMIR Res Protoc
Liver Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Health Needs and Access to Healthcare Services in Migrant Populations in Greece: Data From the Hprolipsis Study
Anagnostou O, Kalpourtzi N, Karakosta A, Terzidis A, Yfantis A, Margalias A, et al.
Cureus . 2025 Mar; 17(1):e78196. PMID: 40027004
Introduction Migration to Greece continues with a constant influx of immigrants from several countries. The importance and necessity of data related to migrants' health and needs are widely recognized, yet...
2.
Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
Koustenis K, Anagnostou O, Kranidioti H, Vasileiadi S, Antonakaki P, Koutli E, et al.
Ann Gastroenterol . 2020 Mar; 33(2):195-201. PMID: 32127741
Background: Direct-acting antivirals (DAAs) offer high cure rates in people who inject drugs (PWID) with hepatitis C virus (HCV) infection. There are concerns regarding lower response rates among PWID in...
3.
Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys
Touloumi G, Karakosta A, Sypsa V, Petraki I, Anagnostou O, Terzidis A, et al.
JMIR Res Protoc . 2020 Feb; 9(1):e13578. PMID: 32004142
Background: Although infectious diseases are globally on the decline, they remain a major global public health problem. Among them, the hepatitis B virus (HBV) or hepatitis C virus (HCV) and...
4.
A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study
Gountas I, Sypsa V, Papatheodoridis G, Paraskevis D, Kalamitsis G, Anagnostou O, et al.
J Viral Hepat . 2019 Jul; 26(11):1311-1317. PMID: 31322302
People who inject drugs (PWID) comprise one of the major transmission risk groups for human immunodeficiency virus (HIV) and hepatitis C virus (HCV). In 2011, Athens experienced a large HIV...
5.
Aiming towards hepatitis C virus elimination in Greece
Papatheodoridis G, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, et al.
Ann Gastroenterol . 2019 Jul; 32(4):321-329. PMID: 31263353
There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic...
6.
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, et al.
Ann Gastroenterol . 2018 Sep; 31(5):598-603. PMID: 30174397
Background: It is estimated that 17,000 people who inject drugs (PWID) in Greece have hepatitis C virus (HCV) viremia. The aim of our study was to explore the characteristics of...
7.
The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis
Borges A, Neuhaus J, Sharma S, Neaton J, Henry K, Anagnostou O, et al.
J Infect Dis . 2018 Jul; 219(2):254-263. PMID: 30032171
Background: Pooled data from the SMART and START trials were used to compare deferred/intermittent versus immediate/continuous antiretroviral therapy (ART) on disease risk. Methods: Endpoints assessed were AIDS, serious non-AIDS (SNA),...
8.
Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, et al.
Addiction . 2017 Jan; 112(7):1290-1299. PMID: 28107585
Aims: To project the impact of scaling-up oral anti-viral therapy and harm reduction on chronic hepatitis C (CHC) prevalence and incidence among people who inject drugs (PWID) in Greece, to...
9.
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C
Manolakopoulos S, Deutsch M, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis G, et al.
Liver Int . 2010 Sep; 30(10):1454-60. PMID: 20846344
Introduction And Aims: International guidelines and routine clinical practice express concerns about antiviral treatment in intravenous drug users (IDUs). We analysed the effect of IDU and/or substitution therapy on chronic...
10.
Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance
Dimitroulopoulos D, Petroulaki E, Manolakopoulos S, Anagnostou O, Tsaklakidou D, Xinopoulos D, et al.
Eur J Gastroenterol Hepatol . 2009 Nov; 21(12):1407-12. PMID: 19916203
Introduction: Chronic hepatitis C virus infection (HCV) is the most common infectious disease among intravenous drug users. Aims: To determine and compare compliance rates between two groups of chronic HCV...